Stay updated with breaking news from Molecular Testing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's KRAS Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging KRAS...
Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.
David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC
Key opinion leaders in the field of non–small cell lung cancer management discuss the role of immunotherapy in patients with concomitant KRAS and KEAP1/STK11 mutations.
Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.